Serum chromogranin A correlation with tumor burden in metastatic small bowel carcinoid patients

#29

Introduction: Patients with neuroendocrine tumors may have clinical courses that range from fairly indolent to more aggressive. Cross–sectional studies, nuclear imaging and biochemical markers are often used to monitor disease progression. Optimal surveillance tests and intervals have not been firmly established. Studies suggest that chromogranin A (CgA) may be a surrogate marker for tumor burden.

Aim(s): The aim of this study was to correlate serum CgA and serotonin levels with radiologically assessed hepatic tumor burden in patients with metastatic small bowel carcinoid.

Materials and methods: Clinical database query identified 57 patients with small bowel carcinoids with hepatic metastases. As part of clinical care, this cohort was evaluated with surveillance CT scans and serum biomarkers at the discretion of their physicians from 2001 to 2009. RECIST (Response Evaluation Criteria in Solid Tumors) guidelines with assessment of sum diameter of five largest hepatic metastases were applied by two independent observers to CT scans done within six months of serum biomarker collection. Sums were correlated with CgA and serotonin using Pearson correlation.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Curran T

Authors: Schneiderman M, Curran T, Lee K, Warner R, Kim M,

Keywords: carcinoid, metastatic, biomarkers, radiology, chromogranin A,